IMPROVING MYELOFIBROSIS OUTCOMES (2022): REGULAR MONITORING AND EARLY INTERVENTION ARE KEY TO OPTIMISE CARE AND IMPROVE OVERALL SURVIVAL

01 Jul 2022
IMPROVING MYELOFIBROSIS OUTCOMES (2022):
REGULAR MONITORING AND EARLY INTERVENTION ARE KEY
TO OPTIMISE CARE AND IMPROVE OVE
At the recent regional Myeloproliferative Neoplasm (MPN): New Horizons, A Cross-Country Webinar supported by Novartis, Dr Francesco Passamonti, professor of haematology, University Hospital Ospedale di Circolo, Fondazione Macchi, Varese, Italy, addressed the current landscape of treatment surrounding Myelofibrosis (MF) and improving survival outcomes.

Related MIMS Drugs

Editor's Recommendations